{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:59:18Z","timestamp":1781585958722,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Despite advances in treatment, multiple myeloma (MM) remains incurable and results in significant morbidity and mortality. Further research investigating where MM patients die and characterization of end-of-life hospitalizations is needed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We utilized the National Inpatient Sample (NIS) to explore the hospitalization burden of MM patients at the end of their lives.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The percent of patients dying in the hospital as a percent of overall MM deaths ranged from 54% in 2002 to 41.4% in 2017 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Blood transfusions were received in 32.7% of these hospitalizations and infections were present in 47.8% of patients. Palliative care and\/or hospice consultations ranged from 5.3% in 2002 to 31.4% in 2017 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our study demonstrates that patients with MM dying in the hospital have a significant requirement for blood transfusions and have a high infection burden. We also show that palliative care and hospice involvement at the end of life has increased over time but remains low, and that ultimately, inpatient mortality has decreased over time, but MM patients die in the hospital at a higher rate than the general population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08079-x","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T10:03:18Z","timestamp":1617184998000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Hospitalization at the end of life in patients with multiple myeloma"],"prefix":"10.1186","volume":"21","author":[{"given":"Saqib","family":"Abbasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Roller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al-Ola","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Shune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"McClune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Sborov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"issue":"2","key":"8079_CR1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/ejh.13083","volume":"101","author":"I Turesson","year":"2018","unstructured":"Turesson I, Bjorkholm M, Blimark CH, Kristinsson S, Velez R, Landgren O. Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival. Eur J Haematol. 2018;101(2):237\u201344. https:\/\/doi.org\/10.1111\/ejh.13083.","journal-title":"Eur J Haematol"},{"issue":"14","key":"8079_CR2","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1200\/JCO.18.02096","volume":"37","author":"J Mikhael","year":"2019","unstructured":"Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar MV, Kumar S, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. J Clin Oncol. 2019;37(14):1228\u201363. https:\/\/doi.org\/10.1200\/JCO.18.02096.","journal-title":"J Clin Oncol"},{"key":"8079_CR3","doi-asserted-by":"publisher","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122\u20138. https:\/\/doi.org\/10.1038\/leu.2013.313.","DOI":"10.1038\/leu.2013.313"},{"key":"8079_CR4","unstructured":"National Cancer Institute. Myeloma - Cancer Stat Facts. Surveillance, Epidemiology, and End Results (SEER) Program. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed 20 Oct 2020."},{"issue":"36","key":"8079_CR5","doi-asserted-by":"publisher","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","volume":"23","author":"BM Augustson","year":"2005","unstructured":"Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002\u2014Medical Research Council adult Leukaemia working party. J Clin Oncol. 2005;23(36):9219\u201326. https:\/\/doi.org\/10.1200\/JCO.2005.03.2086.","journal-title":"J Clin Oncol"},{"issue":"1","key":"8079_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3324\/haematol.2014.107714","volume":"100","author":"C Blimark","year":"2015","unstructured":"Blimark C, Holmberg E, Mellqvist U-H, Landgren O, Bj\u00f6rkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107\u201313. https:\/\/doi.org\/10.3324\/haematol.2014.107714.","journal-title":"Haematologica"},{"key":"8079_CR7","doi-asserted-by":"publisher","unstructured":"Khera R, Krumholz HM. With Great Power Comes Great Responsibility: Big Data Research From the National Inpatient Sample. Circ Cardiovasc Qual Outcomes. 2017;10(7):e003846. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.117.003846.","DOI":"10.1161\/CIRCOUTCOMES.117.003846"},{"key":"8079_CR8","unstructured":"National Vital Statistics System. Underlying cause of death data, 2000\u20132018. [https:\/\/wonder.cdc.gov\/ucd-icd10.html.]"},{"issue":"11","key":"8079_CR9","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1080\/10428194.2020.1780585","volume":"61","author":"GR Mohyuddin","year":"2020","unstructured":"Mohyuddin GR, Abbasi S, Ripp J, Singh A, Kambhampati S, McClune B. Patients with leukemia dying in the hospital: results of the national inpatient sample and a call to do better. Leuk Lymphoma. 2020;61(11):2760\u20132. https:\/\/doi.org\/10.1080\/10428194.2020.1780585.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"8079_CR10","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1080\/10428194.2020.1719094","volume":"61","author":"S Abbasi","year":"2020","unstructured":"Abbasi S, Britt A, McClune B, Shune L, Kambhampati S, Mohyuddin GR. Inpatient hospitalization's associated cost and mortality in myeloma patients undergoing autologous stem cell transplant: a 13-year analysis of the National Inpatient Sample. Leuk Lymphoma. 2020;61(5):1254\u20136. https:\/\/doi.org\/10.1080\/10428194.2020.1719094.","journal-title":"Leuk Lymphoma"},{"key":"8079_CR11","doi-asserted-by":"publisher","unstructured":"Sedhom R, Kuo PL, Gupta A, et al. Changes in the place of death for older adults with cancer: reason to celebrate or a risk for unintended disparities?\u00a0J Geriatr Oncol. 2020;S1879-4068(20)30480-X. https:\/\/doi.org\/10.1016\/j.jgo.2020.10.008. [published online ahead of print, 2020 Oct 26]","DOI":"10.1016\/j.jgo.2020.10.008"},{"issue":"3","key":"8079_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1182\/bloodadvances.2018023051","volume":"3","author":"F Chino","year":"2019","unstructured":"Chino F, Kamal AH, Chino J, LeBlanc TW. Disparities in place of death for patients with hematological malignancies, 1999 to 2015. Blood Adv. 2019;3(3):333\u20138. https:\/\/doi.org\/10.1182\/bloodadvances.2018023051.","journal-title":"Blood Adv"},{"issue":"22","key":"8079_CR13","doi-asserted-by":"publisher","first-page":"4408","DOI":"10.1002\/cncr.31737","volume":"124","author":"F Chino","year":"2018","unstructured":"Chino F, Kamal AH, Leblanc TW, Zafar SY, Suneja G, Chino JP. Place of death for patients with cancer in the United States, 1999 through 2015: racial, age, and geographic disparities. Cancer. 2018;124(22):4408\u201319. https:\/\/doi.org\/10.1002\/cncr.31737.","journal-title":"Cancer"},{"issue":"1","key":"8079_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.7326\/0003-4819-96-1-47","volume":"96","author":"DG SAVAGE","year":"1982","unstructured":"SAVAGE DG, LINDENBAUM J, Garrett T. Biphasic pattern of bacterial infection in multiple myeloma. Ann Intern Med. 1982;96(1):47\u201350. https:\/\/doi.org\/10.7326\/0003-4819-96-1-47.","journal-title":"Ann Intern Med"},{"issue":"12","key":"8079_CR15","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","volume":"20","author":"MT Drayson","year":"2019","unstructured":"Drayson MT, Bowcock S, Planche T, Iqbal G, Pratt G, Yong K, et al. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol. 2019;20(12):1760\u201372. https:\/\/doi.org\/10.1016\/S1470-2045(19)30506-6.","journal-title":"Lancet Oncol"},{"key":"8079_CR16","unstructured":"Medicare Program; FY 2021 Hospice Wage Index and Payment Rate Update [https:\/\/www.federalregister.gov\/documents\/2020\/08\/04\/2020-16991\/medicare-program-fy-2021-hospice-wage-index-and-payment-rate-update]. Accessed 20 Oct 2020."},{"issue":"7","key":"8079_CR17","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1182\/blood-2018-03-842575","volume":"132","author":"TW LeBlanc","year":"2018","unstructured":"LeBlanc TW, Egan PC, Olszewski AJ. Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia. Blood. 2018;132(7):717\u201326. https:\/\/doi.org\/10.1182\/blood-2018-03-842575.","journal-title":"Blood"},{"issue":"15","key":"8079_CR18","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1182\/bloodadvances.2020001767","volume":"4","author":"PC Egan","year":"2020","unstructured":"Egan PC, LeBlanc TW, Olszewski AJ. End-of-life care quality outcomes among Medicare beneficiaries with hematologic malignancies. Blood Adv. 2020;4(15):3606\u201314. https:\/\/doi.org\/10.1182\/bloodadvances.2020001767.","journal-title":"Blood Adv"},{"issue":"10","key":"8079_CR19","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1377\/hlthaff.2014.0280","volume":"33","author":"GA Brooks","year":"2014","unstructured":"Brooks GA, Li L, Uno H, Hassett MJ, Landon BE, Schrag D. Acute hospital care is the chief driver of regional spending variation in Medicare patients with advanced cancer. Health Aff (Millwood). 2014;33(10):1793\u2013800. https:\/\/doi.org\/10.1377\/hlthaff.2014.0280.","journal-title":"Health Aff (Millwood)"},{"issue":"17","key":"8079_CR20","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1002\/cncr.30735","volume":"123","author":"OO Odejide","year":"2017","unstructured":"Odejide OO, Cronin AM, Earle CC, Tulsky JA, Abel GA. Why are patients with blood cancers more likely to die without hospice? Cancer. 2017;123(17):3377\u201384. https:\/\/doi.org\/10.1002\/cncr.30735.","journal-title":"Cancer"},{"issue":"8","key":"8079_CR21","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3324\/haematol.2018.187609","volume":"103","author":"OO Odejide","year":"2018","unstructured":"Odejide OO, Li L, Cronin AM, Murillo A, Richardson PG, Anderson KC, et al. Meaningful changes in end-of-life care among patients with myeloma. haematologica. 2018;103(8):1380\u20139.","journal-title":"haematologica"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08079-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-021-08079-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08079-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T10:05:56Z","timestamp":1617185156000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08079-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8079"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08079-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,31]]},"assertion":[{"value":"30 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A, as no humans were involved in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the authors have any conflicts of interest to declare other than the following for Dr. Sborov: consulting for Janssen, SkylinDx, GlaxoSmithKline, Legend Biotech, Amgen and Celgene.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"339"}}